

THE 2017 POSITIVELY AWARE HEPATITIS DRUG CHART



Drug chart information is current as of August 23, 2017. The complete POSITIVELY AWARE 2017 HEPATITIS B & C DRUG GUIDE is available at positivelyaware.com.

Hepatitis B is treated with either an oral antiviral medication over the long-term, or with an injectable immunostimulator that one takes for 6–12 months. See drug page or package insert for complete information on dosage and treatment duration requirements.



Epivir-HBV

lamivudine, or 3TC

ADULT: One 100 mg tablet once daily, with or without food; PEDIATRIC (AGE 2–17): 3 mg per kg of weight, for no more than 100 per day. Oral solution (liquid) available for dosages less than 100 mg. Dose adjustments needed for individuals with kidney disease. See drug page and consult a medical provider for more detail.



Baraclude

entecavir, ETV

ADULT (AGE 16 AND OLDER): Treatment naïve with no resistance, one 0.5 mg tablet once daily on an empty stomach (no food 2 hours before or 2 hours after taking pill). If resistant to lamivudine or telbivudine (brand name Tyzeka, discontinued for use since 2016), 1 mg once daily on an empty stomach. ADULT WITH DECOMPENSATED LIVER DISEASE: 1 mg once per day. Dose adjustments needed for individuals with kidney disease. See package insert and consult a medical provider for more detail. PEDIATRIC (AGE 2-15): weight-based dosing required. See drug page and consult a medical provider for more detail.



Hepsera

adefovir, ADV

ADULT (AGE 12 AND OLDER): One 10 mg tablet once per day, with or without food. Dose adjustments needed for individuals with kidney disease. Not recommended for use in children under age 12.



Viread

tenofovir disoproxil fumarate, TDF

ADULT (AGE 12 AND OLDER): One 300 mg tablet once per day, with or without food. Dose adjustment needed for individuals with kidney disease. See drug page and consult a medical provider for more detail. Not recommended for use in children under age 12.



Vemlidy

tenofovir alafenamide, TAF

ADULT: One 25 mg tablet once per day, with food. Not recommended for individuals with kidney disease if creatinine clearance is below 15 mL per minute or for individuals with decompensated cirrhosis. Not recommended for use in children.



Pegasys

peginterferon alfa-2a, PEG-IFN

ADULT: 180 mcg injected once per week, no food restrictions. PEDIATRIC: Not FDA approved, but off-label use is possible. Consult with a medical provider for more information.

Hepatitis C is treated with oral antiviral medication(s), typically for about 2–3 months. Each drug is recommended for use as a fixed-dose combination (FDC) or in combination with other drugs. See drug page or package insert for complete information on dosage and treatment duration requirements.



Harvoni

ledipasvir/sofosbuvir, or LDV/SOF

GENOTYPE 1 4 5 6

One FDC tablet once daily, with or without food. FDA approved for pediatric patients age 12 or older or at least 35 kg (77 pounds). FDA approved for HIV/HCV co-infection.



Sovaldi

sofosbuvir, SOF, or SOV

GENOTYPE 1 2 3 4

One FDC tablet once daily, with or without food; must be taken in combination with another DAA, ribavirin, or ribavirin plus pegylated interferon. Sovaldi should never be taken by itself. FDA approved for HIV/HCV co-infection.




Epclusa

sofosbuvir/velpatasvir, or SOF/VEL

GENOTYPE 1 2 3 4 5 6

One FDC tablet once daily, with or without food. Ribavirin may be included in patients with decompensated cirrhosis. Not FDA approved for HIV/HCV co-infection, but off-label use is possible.



Zepatier

grazoprevir/elbasvir, or GZR/EBR

GENOTYPE 1 4

One FDC tablet once daily, with or without food. FDA approved for HIV/HCV co-infection.



Daklinza

daclatasvir, or DCV

GENOTYPE 1 3

One 60 mg tablet once daily with or without food; 30 mg and 90 mg tablets are also available. Must be taken in combination with Sovaldi (sofosbuvir); ribavirin may be included for some genotypes, treatment-experienced patients, or for those with cirrhosis. FDA approved for HIV/HCV co-infection.



Viekira XR

ombitasvir/paritaprevir/ritonavir plus dasabuvir, or OMB/PTV/r + DAS

GENOTYPE 1

Three FDC tablets once daily with food; may be taken with ribavirin depending on genotype 1 subtype and compensated cirrhosis. FDA approved for HIV/HCV co-infection.



Technivie

ombitasvir/paritaprevir/ritonavir, or OMB/PTV-r

GENOTYPE 4

Two FDC tablets once daily with food; must be taken with ribavirin. FDA approved for HIV/HCV co-infection.



Olysio

simeprevir, or SMV

GENOTYPE 1 4

One capsule once daily, with food; do not crush or dissolve the capsule; Olysio should never be taken by itself. Olysio + Peg IFN + RBV is approved for HIV/HCV co-infection, but it is highly unlikely to be prescribed. FDA approved for HIV/HCV co-infection.



Copegus; Moderiba; Ribasphere

ribavirin, or RBV

GENOTYPE 1 2 3 4 5 6

Ribavirin dosage depends upon the brand, and is given in either fixed doses or in doses related to weight (weight-based). The dose range is 800 mg to 1,400 mg per day taken in two divided doses. Depending upon the manufacturer, tablets are available in 200 mg, 400 mg, 500 mg, and 600 mg. A liquid dose is also available. Must be taken with food. FDA approved for HIV/HCV co-infection. Generic available.



Mavyret

glecaprevir/pibrentasvir, or G/P

GENOTYPE 1 2 3 4 5 6

Three FDC tablets once daily with food; may be taken by those with compensated cirrhosis. FDA approved for HIV/HCV co-infection.



Vosevi

sofosbuvir/velpatasvir/voxilaprevir, or SOF/VEL/VOX

GENOTYPE 1 2 3 4 5 6

One FDC tablet once daily, with food; may be taken by those with compensated cirrhosis.

THE POSITIVELY AWARE 2017 HEPATITIS B & C DRUG CHART IS SPONSORED BY



©2017 POSITIVELY AWARE